Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential

After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.

The migraine market has been a somewhat static space for nearly two decades, dominated by over-the-counter products and a dominant class that went generic. More recent launches and near-term candidates tend to be reformulations of existing drug classes, such as triptans and ergotamine, though there are some antibody therapies mostly in early- to mid-stage development. But those companies see significant opportunity in the space.

Migraine headaches comprise really two indications – treatment of acute migraine headaches in patients who have anywhere from one to...

More from Europe

More from Geography